A session at the AACR Annual Meeting 2015. Photo by AACR/Todd Buchanan.

The AACR Annual Meeting 2015 took place April 18-22 in Philadelphia, Pennsylvania.

Inhibitor promotes chemosensitization in CLL

Print Friendly, PDF & Email


CLL_BM.jpg
CLL cells

A DNA-dependent protein kinase (DNA-PK) inhibitor can sensitize chronic lymphocytic leukemia (CLL) cells to chemotherapy, according to preclinical research. The inhibitor, NDD0004, sensitized CLL cells—even those from patients with high-risk cytogenetics—to treatment with mitoxantrone. However, not all CLL samples were sensitive to treatment, so researchers are now trying to determine which patients might... [Read Article]

Print Friendly, PDF & Email

Study helps explain how drug fights DLBCL

Print Friendly, PDF & Email


researchers_microscope_NCI_Rhoda_Baer_230.jpg
Researchers in the lab
Photo by Rhoda Baer

The tumor microenvironment may play a key role in treatment with CUDC-427, according to researchers. Their experiments showed that certain diffuse large B-cell lymphoma (DLBCL) cell lines were sensitive to CUDC-427, and others were not. However, co-culturing with stromal cells or TNF family ligands made resistant... [Read Article]

Print Friendly, PDF & Email

Inhibitor may benefit certain ALL patients

Print Friendly, PDF & Email


lab_mouse_240.jpg
Lab mouse

Results of preclinical research suggest the BCL-2 inhibitor ABT-199 (venetoclax) may be effective in certain pediatric patients with acute lymphoblastic leukemia (ALL). In xenograft models of various ALL subtypes, ABT-199 produced an objective response rate below 30%. However, additional analyses unearthed information that could potentially help us identify which ALL patients might respond... [Read Article]

Print Friendly, PDF & Email

Agent preferentially targets FLT3-ITD AML

Print Friendly, PDF & Email


AML_in_bone_marrow_240.jpg
AML cells in the bone marrow

Preclinical research suggests a novel agent has preferential activity in acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations. The agent, VNLG-152, proved more cytotoxic in AML cell lines and patient samples with FLT3-ITD than in samples and cell lines with wild-type FLT3. Exactly... [Read Article]

Print Friendly, PDF & Email

Defining the role of TAMs in DLBCL

Print Friendly, PDF & Email


macrophage_in_a_mouse_Flickr_230.jpg
A macrophage stretching its
pseudopodia to engulf particles

New research suggests the prognostic value of tumor-associated macrophages (TAMs) is disease-specific as well as treatment-specific. Investigators set out to determine if TAMs have a negative prognostic impact in diffuse large B-cell lymphoma (DLBCL), as previous studies produced conflicting results. The team found that higher TAM... [Read Article]

Print Friendly, PDF & Email

Susceptibility to 2nd cancers in WM/LPL survivors

Print Friendly, PDF & Email


AACR_2015_man_registration_240_brighter.jpg
AACR Annual Meeting 2015

A retrospective study has revealed factors that appear to influence a person’s susceptibility to Waldenström’s macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) and other malignancies. Study investigators looked at patients diagnosed with WM or LPL over a 20-year period and found about a 50% excess of second primary cancers in this population. The patients... [Read Article]

Print Friendly, PDF & Email

MKIs can overcome resistance in CML

Print Friendly, PDF & Email


AACR_2015_banner_edited_240.jpg
AACR Annual Meeting 2015

Two multikinase inhibitors (MKIs) can treat chronic myeloid leukemia (CML) that is resistant to other inhibitors, according to preclinical research. A series of in vitro experiments showed that the MKIs, sorafenib and axitinib, can overcome treatment resistance mediated by hyperactivation of the Src kinase Lyn, overexpression of the docking protein Gab2,... [Read Article]

Print Friendly, PDF & Email

Molecule increases TRAIL expression to fight NHL

Print Friendly, PDF & Email


AACR_2015_hashtag_220.jpg
Inside the Pennsylvania
Convention Center, site of the
AACR Annual Meeting 2015

When current treatment approaches failed to save a young patient with non-Hodgkin lymphoma (NHL), a researcher from The Children’s Hospital of Philadelphia was driven to investigate new therapeutic options. The investigation led the researcher, Mala Talekar, MBBS, to ONC201 (formerly TIC10),... [Read Article]

Print Friendly, PDF & Email

CDK inhibitor proves active against AML, ALL

Print Friendly, PDF & Email


lab_mouse_245.jpg
Lab mouse

Preclinical research suggests a cyclin-dependent kinase (CDK) inhibitor is active against acute leukemias, particularly those with mixed-lineage leukemia rearrangements (MLL-r). CYC065 selectively inhibits CDK2, which drives cell-cycle transition and activates major DNA double-strand break repair pathways; CDK5, which drives metastatic spread; and CDK9, which regulates the transcription of genes important for the proliferation... [Read Article]

Print Friendly, PDF & Email